嘉应制药遭证监会立案调查，直指公司内控！

Core Viewpoint - Guangdong Jiaying Pharmaceutical Co., Ltd. is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure, leading to significant stock price declines and market capitalization loss [1][3]. Financial Performance - As of December 31, 2024, the company reported revenue of 376 million yuan, a year-on-year decrease of 29.46%, and a net profit attributable to shareholders of 20.61 million yuan, down 39.94% year-on-year [4]. Internal Control Issues - The investigation was triggered by major internal control deficiencies, highlighted in the company's self-evaluation report, which received a qualified opinion from Zhonghua Accounting Firm [6]. - From September 2024 to January 2025, Jiaying Pharmaceutical's wholly-owned subsidiary transferred a total of 170 million yuan to related party Hunan Yaojuneng Pharmaceutical Co., Ltd. without board approval, using a "beginning of month transfer, end of month return" method to obscure the transactions [6]. - In the fourth quarter of 2024, the company engaged in related party transactions totaling 10.39 million yuan with its second-largest shareholder and other related parties, failing to follow proper board review and disclosure procedures [6].